Funding Support Center
DF/HCC Sponsored Funding
The Dana-Farber/Harvard Cancer Center (DF/HCC) Specialized Program in Research Excellence (SPORE) in Prostate Cancer is currently seeking applications for Translational Projects in Prostate Cancer.
The applicant (PI) or co-PI must be on the faculty at Harvard Medical School or Harvard School of Public Health at the level of Assistant Professor or higher. Research may span the disciplines of basic biology, population science, or clinical science including imaging. Proposals will be accepted from investigators leading existing projects and pilot projects as well as currently non-SPORE funded investigators. All basic research supported by the SPORE must have a plan for translation into application or studies in humans, since the purpose of this program is to promote translational research in prostate cancer. Similarly all clinical research needs to have a strong wet or dry lab component. As such, basic or population scientists need to partner with clinical scientists to ensure a plan for clinical application. Collaboration between investigators currently working in this field is strongly encouraged.
We are seeking pre-applications in the form of a 5-page proposal that contains background, specific aims, research plan and plans for translation (see below). These pre-applications will be judged on their scientific merit, translational potential and the potential for contribution to the overall status of the DF/HCC Prostate Cancer Program/Prostate Cancer SPORE. Some pre-applications may be selected to present their proposal at a project review session (time and place to be determined). Ultimately, only 1-2 applicants will be selected. This award will be granted at a level of approximately $100-$125K in yearly direct costs for 2 years (07/01/2010 – 6/30/2012). The awardees will become members of the DF/HCC Prostate Cancer Program and the DF/HCC Prostate Cancer SPORE and would be expected to attend SPORE activities (meetings, retreats, research presentations). Women and minority candidates are encouraged to apply.
A Letter of Intent is required and due by Wednesday, July 15th, 2009. Please address to Dr. Philip W. Kantoff and forward to Roxanne Elkashawy (see below for contact information) – we will accept original letters as well as electronic versions.
Applications are due Thursday, October 15th, 2009, and should consist of the following:
1) NIH Biosketch of all key personnel
2) Current Other Support pages for all key personnel
2) A research proposal not to exceed 5 pages that is structured as follows:
A. Specific Aims
B. Background and Relevance
C. Preliminary Data
D. Experimental Procedures
E. Plan for Translation to Clinical Application
3) Appendix with reprints etc. are permitted
Application Submission Instructions: One PDF document including the above required documentation should be emailed to Roxanne_Elkashawy@dfci.harvard.edu by Thursday, October 15th, 2009. In addition, please deliver 10 hardcopies of the application to Roxanne Elkashawy (D1230) by Thursday, October 15h, 2009. For all inquiries, please contact Roxanne Elkashawy by email (see above) or phone (617.632.6534).